179 related articles for article (PubMed ID: 30606762)
1. Endothelial Cell-Targeted Deletion of PPAR
Akiyama TE; Skelhorne-Gross GE; Lightbody ED; Rubino RE; Shi JY; McNamara LA; Sharma N; Zycband EI; Gonzalez FJ; Liu H; Woods JW; Chang CH; Berger JP; Nicol CJB
J Pharmacol Exp Ther; 2019 Mar; 368(3):514-523. PubMed ID: 30606762
[TBL] [Abstract][Full Text] [Related]
2. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM
Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-γ in capillary endothelia promotes fatty acid uptake by heart during long-term fasting.
Goto K; Iso T; Hanaoka H; Yamaguchi A; Suga T; Hattori A; Irie Y; Shinagawa Y; Matsui H; Syamsunarno MR; Matsui M; Haque A; Arai M; Kunimoto F; Yokoyama T; Endo K; Gonzalez FJ; Kurabayashi M
J Am Heart Assoc; 2013 Jan; 2(1):e004861. PubMed ID: 23525438
[TBL] [Abstract][Full Text] [Related]
4. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity.
Lee SM; Muratalla J; Diaz-Ruiz A; Remon-Ruiz P; McCann M; Liew CW; Kineman RD; Cordoba-Chacon J
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34417811
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
[TBL] [Abstract][Full Text] [Related]
8. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.
Sotiropoulos KB; Clermont A; Yasuda Y; Rask-Madsen C; Mastumoto M; Takahashi J; Della Vecchia K; Kondo T; Aiello LP; King GL
FASEB J; 2006 Jun; 20(8):1203-5. PubMed ID: 16672634
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
Mallon PW; Sedwell R; Rogers G; Nolan D; Unemori P; Hoy J; Samaras K; Kelleher A; Emery S; Cooper DA; Carr A;
J Infect Dis; 2008 Dec; 198(12):1794-803. PubMed ID: 18954260
[TBL] [Abstract][Full Text] [Related]
10. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Zhang H; Zhang A; Kohan DE; Nelson RD; Gonzalez FJ; Yang T
Proc Natl Acad Sci U S A; 2005 Jun; 102(26):9406-11. PubMed ID: 15956187
[TBL] [Abstract][Full Text] [Related]
11. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.
Zhou L; Liu G; Jia Z; Yang KT; Sun Y; Kakizoe Y; Liu M; Zhou S; Chen R; Yang B; Yang T
Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1491-7. PubMed ID: 24005472
[TBL] [Abstract][Full Text] [Related]
13. PPARγ activation but not PPARγ haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors.
Kotlinowski J; Grochot-Przeczek A; Taha H; Kozakowska M; Pilecki B; Skrzypek K; Bartelik A; Derlacz R; Horrevoets AJ; Pap A; Nagy L; Dulak J; Jozkowicz A
Cardiovasc Diabetol; 2014 Nov; 13():150. PubMed ID: 25361524
[TBL] [Abstract][Full Text] [Related]
14. Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.
Guo X; Li H; Xu H; Halim V; Thomas LN; Woo SL; Huo Y; Chen YE; Sturino JM; Wu C
J Nutr Biochem; 2013 May; 24(5):770-5. PubMed ID: 22841546
[TBL] [Abstract][Full Text] [Related]
15. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
16. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.
Chang CS; Tsai PJ; Sung JM; Chen JY; Ho LC; Pandya K; Maeda N; Tsai YS
Am J Pathol; 2014 Feb; 184(2):442-53. PubMed ID: 24287404
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.
Muhlhausler BS; Morrison JL; McMillen IC
Endocrinology; 2009 Sep; 150(9):4287-94. PubMed ID: 19520784
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver.
Lee SM; Pusec CM; Norris GH; De Jesus A; Diaz-Ruiz A; Muratalla J; Sarmento-Cabral A; Guzman G; Layden BT; Cordoba-Chacon J
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1291-1311. PubMed ID: 33444819
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
[TBL] [Abstract][Full Text] [Related]
20. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
